Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 2/20 | 0.37 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.37 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 3/20 | 0.31 |
| ▸ | CA1 | P00915 | 3/20 | 0.31 |
| ▸ | CA2 | P00918 | 3/20 | 0.31 |
| ▸ | CA9 | Q16790 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29289996 | 0.86 | — | — | |
| SCHEMBL28468503 | 0.82 | GNAI3 (0.35) | GNAI3GNAO1GNAI1HSD17B10 | |
| SCHEMBL28131967 | 0.82 | — | — | |
| SCHEMBL28754064 | 0.80 | GNAI3 (0.34) | GNAI3GNAO1GNAI1HSD17B10 | |
| SCHEMBL8897918 | 0.78 | GNAI3 (0.38) | GNAI3GNAO1GNAI1HSD17B10CA12 | |
| SCHEMBL5320211 | 0.77 | — | — | |
| SCHEMBL1459326 | 0.76 | GNAI3 (0.44) | GNAI3GNAO1GNAI1CA12CA1 | |
| SCHEMBL3910316 | 0.76 | GNAI3 (0.37) | GNAI3GNAO1GNAI1CA12CA1 | |
| SCHEMBL4436078 | 0.76 | HSD17B10 (0.48) | GNAI3GNAO1GNAI1HSD17B10CA12 | |
| SCHEMBL6068186 | 0.75 | HTT (0.36) | HSD17B10CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106188079-A | 7 piperazine thioureas of camptothecine, preparation method and purposes | 兰州大学 | 2016-12-07 | — | — | CN | claimed |
| US-20230100559-A1 | Compositions and Methods for Treatment of Disease by Manipulation of Serine Metabolism | THE TRUSTEES OF PRINCETON UNIVERSITY | 2023-03-30 | — | — | US | disclosed |
| CN-106188079-A | 7 piperazine thioureas of camptothecine, preparation method and purposes | 兰州大学 | 2016-12-07 | — | — | CN | disclosed |
| US-8022071-B2 | Nitrogenous heterocyclic compounds | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| EP-1309568-B1 | [(quinazolin-4-yl)piperazin-4-yl]thiocarboxamide compounds as inhibitors of the phosphorylation of a PDGF receptor | MILLENNIUM PHARM INC (US) | 2011-02-16 | — | — | EP | disclosed |
| US-20090176780-A1 | NITROGENOUS HETEROCYCLIC COMPOUNDS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-7329655-B2 | Nitrogenous heterocyclic compounds | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-02-12 | — | — | US | disclosed |
| CN-1906199-A | Diazaindole-dicarbonyl-piperazinyl antiviral agents | BRISTOL MYERS SQUIBB CO (US) | 2007-01-31 | — | — | CN | disclosed |
| US-20040176594-A1 | Nitrogenous heterocyclic compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2004-09-09 | — | — | US | disclosed |
| EP-1309568-A2 | NITROGENOUS HETEROCYCLIC COMPOUNDS | Millennium Pharmaceuticals, Inc. (US) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002016361-A2 | NITROGENOUS HETEROCYCLIC COMPOUNDS | COR THERAPEUTICS, INC. (US) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230100559-A1 | Compositions and Methods for Treatment of Disease by Manipulation of Serine Metabolism | SHMT2, PC, ME2 | GNAI3 1700/4885GNAO1 1177/4885GNAI1 1418/4885 |
| US-20040176594-A1 | Nitrogenous heterocyclic compounds | WNK2, NPR1, NPR3 | GNAI3 433/4885GNAO1 385/4885GNAI1 439/4885 |
| US-20090176780-A1 | NITROGENOUS HETEROCYCLIC COMPOUNDS | WNK2, CDK5, WNK1 | GNAI3 472/4885GNAO1 625/4885GNAI1 492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.